Clin2
NCT06138509Possibly a fitRecruiting

Serotonin levels in children with albinism

Oculocutaneous Albinism

Part of Blood & lymphatic, Eyes & vision, Genetic & congenital, Hormones & metabolism, Skin clinical trials.

This study measures blood serotonin levels in children with albinism compared to children without the condition. It aims to learn if serotonin plays a role in albinism, which could help future treatments.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
160 people
Ages
2 years to 17 years
Study type
Observational

Who can take part

  • For children with albinism: ages 2 to 17 years old.
  • For children with albinism: being seen at the MAGEC-Necker reference center.
  • For children without albinism (controls): ages 2 to 17 years old and having a blood test at Necker hospital.
  • For controls: normal results from routine blood tests (CBC and CRP).
  • For controls: parent or guardian does not object after receiving study information.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06345976Recruiting
How albinism affects daily vision and activities

This study is for adults with any type of albinism. It looks at how albinism affects your everyday vision and activities through a simple questionnaire.

Paris
NCT04925349Recruiting
Study blood immune patterns in several rare brain diseases

This study looks at immune cells in blood to better understand rare brain conditions caused by genetic changes. It may help researchers understand why symptoms happen and how the immune system is involved.

Le Kremlin-Bicêtre
NCT07313618Recruiting· Early Phase 1
Gene therapy for children with oculocutaneous albinism type 1

This trial tests a single injection of JWK010 gene therapy for children aged 5 to 12 with OCA1A albinism. The therapy is given into the eye to try to improve vision, and is meant for those who have not had gene therapy before.

Chengdu, Sichuan
NCT07400913Not yet recruiting
Using advanced DNA sequencing to diagnose rare diseases

This trial uses a new DNA sequencing method that reads long stretches of DNA to find genetic causes of rare diseases. It is for people who have intellectual development disorders or albinism and have not yet gotten a clear genetic diagnosis from standard tests.

Bordeaux
NCT04461444Recruiting
Cohort study for Bardet-Biedl and Alström syndromes

This study follows people with Bardet-Biedl syndrome (BBS) or Alström syndrome (ALMS) to spot early vision, metabolic (body chemistry/energy), and kidney problems. You may be asked to have clinical checks over time to help researchers better understand how these complications develop.

Strasbourg
NCT02168868Recruiting
Blood tests to find autism-related protein signals

This study looks at blood samples from children (and sometimes parents) to see if certain protein patterns can help identify or better understand autism spectrum disorder. The results could support finding “biomarkers,” which are measurable signs that may guide future research or care.

Jerusalem

Hear when a new Oculocutaneous Albinism trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.